The common PNPLA3 variant p.I148M is associated with liver fat contents as quantified by controlled attenuation parameter (CAP)

Liver International

Volumn 36, Issue 3, 2016, Pages 418-426

  Arslanow, Anita ^a   Stokes, Caroline S ^a   Weber, Susanne N ^a   Grünhage, Frank ^a   Lammert, Frank ^a   Krawczyk, Marcin ^a,b  

^a SAARLAND UNIVERSITY   (Germany)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Adiponutrin; Elastography; Non alcoholic fatty liver disease; TM6SF2

Indexed keywords

AMINOTRANSFERASE; PATATIN LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG; ADIPONUTRIN, HUMAN; MEMBRANE PROTEIN; TRIACYLGLYCEROL LIPASE;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; CONTROLLED ATTENUATION PARAMETER; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; ELASTOGRAPHY; ENZYME ACTIVITY; FAT CONTENT; FATTY LIVER; FEMALE; GENE MUTATION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; ADOLESCENT; CASE CONTROL STUDY; ENZYMOLOGY; GENE FREQUENCY; GENETIC ASSOCIATION STUDY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; LIVER; MIDDLE AGED; MULTIVARIATE ANALYSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; ODDS RATIO; PATHOLOGY; PHENOTYPE; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; YOUNG ADULT;

ADIPOSITY; ADOLESCENT; ADULT; AGED; BODY MASS INDEX; CASE-CONTROL STUDIES; ELASTICITY IMAGING TECHNIQUES; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LINEAR MODELS; LIPASE; LIVER; LOGISTIC MODELS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; ODDS RATIO; PHENOTYPE; POLYMORPHISM, GENETIC; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; YOUNG ADULT;

EID: 84958842651     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12937     Document Type: Article

References (40)

1. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 2013; 58: 593-608.
2. Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 2013; 10: 656-65.
3. Castera L, Vilgrain V, Angulo P. Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol 2013; 10: 666-75.
4. Cheung CL, Lam KS, Wong IC, Cheung BM. Non-invasive score identifies ultrasonography-diagnosed non-alcoholic fatty liver disease and predicts mortality in the USA. BMC Med 2014; 12: 154.
5. Polyzos SA, Mantzoros CS. Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease. Metabolism 2014; 63: 161-7.
6. Campbell MS, Reddy KR. Review article: the evolving role of liver biopsy. Aliment Pharmacol Ther 2004; 20: 249-59.
7. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-906.
8. Sasso M, Beaugrand M, de Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010; 36: 1825-35.
9. Carvalhana S, Leitao J, Alves AC, Bourbon M, Cortez-Pinto H. How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound. Liver Int 2014; 34: e111-7.
10. ®: validation in chronic hepatitis C. J Viral Hepatitis 2012; 19: 244-53.
11. de Ledinghen V, Vergniol J, Foucher J, Merrouche W, le Bail B. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int 2012; 32: 911-8.
12. Masaki K, Takaki S, Hyogo H, et al. Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases. Hepatol Res 2013; 43: 1182-9.
13. Ferraioli G, Tinelli C, Lissandrin R, et al. Controlled attenuation parameter for evaluating liver steatosis in chronic viral hepatitis. World J Gastroenterol 2014; 20: 6626-31.
14. Hwang S, Yu YD, Park GC, et al. Bioelectrical impedance analysis for evaluation of donor hepatic steatosis in living-donor liver transplantation. Transpl Proc 2010; 42: 1492-6.
15. Krawczyk M, Bonfrate L, Portincasa P. Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol 2010; 24: 695-708.
16. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461-5.
17. Valenti L, Al-Serri A, Daly AK, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51: 1209-17.
18. Krawczyk M, Grünhage F, Zimmer V, Lammert F. Variant adiponutrin (PNPLA3) represents a common fibrosis risk gene: non-invasive elastography-based study in chronic liver disease. J Hepatol 2011; 55: 299-306.
19. Shen JH, Li YL, Li D, et al. The rs738409 (I148M) variant of the PNPLA3 gene and cirrhosis: a meta-analysis. J Lipid Res 2015; 56: 167-75.
20. Smagris E, Basuray S, Li J, et al. Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology 2015; 61: 108-18.
21. Krawczyk M, Portincasa P, Lammert F. PNPLA3-associated steatohepatitis: toward a gene-based classification of fatty liver disease. Semin Liver Dis 2013; 33: 369-79.
22. Sookoian S, Castano GO, Scian R, et al. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity. Hepatology 2015; 61: 515-25.
23. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48: 835-47.
24. Boursier J, Zarski JP, De Ledinghen V, et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology 2013; 57: 1182-91.
25. Gerstenmaier JF, Gibson RN. Ultrasound in chronic liver disease. Insights Imaging 2014; 5: 441-55.
26. Shi KQ, Tang JZ, Zhu XL, et al. Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: a meta-analysis of diagnostic accuracy. J Gastroenterol Hepatol 2014; 29: 1149-58.
27. Krawczyk M, Grünhage F, Lammert F. Identification of combined genetic determinants of liver stiffness within the SREBP1c-PNPLA3 pathway. Int J Mol Sci 2013; 14: 21153-66.
28. Grünhage F, Hochrath K, Krawczyk M, et al. Common genetic variation in vitamin D metabolism is associated with liver stiffness. Hepatology 2012; 56: 1883-91.
29. Karlas T, Petroff D, Garnov N, et al. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PLoS ONE 2014; 9: e91987.
30. Shen J, Wong GL, Chan HL, et al. PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. Aliment Pharmacol Ther 2014; 39: 532-9.
31. Pirazzi C, Valenti L, Motta BM, et al. PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Hum Mol Genet 2014; 23: 4077-85.
32. Dongiovanni P, Donati B, Fares R, et al. PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol 2013; 19: 6969-78.
33. Pingitore P, Pirazzi C, Mancina RM, et al. Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function. Biochim Biophys Acta 2014;1841:574-80.
34. Kumari M, Schoiswohl G, Chitraju C, et al. Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. Cell Metab 2012; 15: 691-702.
35. Anstee QM, Day CP. The genetics of NAFLD. Nat Rev Gastroenterol Hepatol 2013; 10: 645-55.
36. Kozlitina J, Smagris E, Stender S, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2014; 46: 352-6.
37. Liu YL, Reeves HL, Burt AD, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun 2014; 5: 4309.
38. Dongiovanni P, Petta S, Maglio C, et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 2015; 61: 506-14.
39. Mahdessian H, Taxiarchis A, Popov S, et al. TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content. Proc Natl Acad Sci USA 2014; 111: 8913-8.
40. Karlas T, Kollmeier J, Bohm S, et al. Noninvasive characterization of graft steatosis after liver transplantation. Scand J Gastroenterol 2015; 50: 224-32.